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INTRODUCTION 25
Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of fat 26 in hepatocytes in the absence of excessive alcohol consumption. NAFLD is a spectrum 27 of liver diseases with its first stage, known as 'simple steatosis', defined as liver fat 28 content >5% of total liver weight. Simple steatosis can progress to non-alcoholic 29 steatohepatitis (NASH), fibrosis, cirrhosis, and eventually hepatocellular carcinoma. In 30 NAFLD, triglycerides accumulate in hepatocytes and liver insulin sensitivity is 31 diminished, promoting hepatic gluconeogenesis, thereby raising the risk of type 2 32 diabetes (T2D) or exacerbating the disease pathology in those with diabetes (1-5). 33 34 The prevalence of NAFLD is thought to be around 20-40% in the general population in 35
Western countries, with an increasing trend across the world, imposing a substantial 36 economic and public health burden (6) (7) (8) (9) . However, the exact prevalence of NAFLD 37 has not been clarified, in part because liver fat is difficult to accurately assess. Liver 38 biopsy, magnetic resonance imaging (MRI), ultrasounds and liver enzyme tests are 39 often used for NAFLD diagnosis, but the invasive nature of biopsies, the high costs of 40 MRI scans, the non-quantitative nature and low sensitivity of conventional ultrasounds, 41 and the low accuracy of liver enzyme tests are significant limitations (10) (11) (12) . To 42 address this gap, several liver fat prediction indices have been developed, but none of 43 these has sufficiently high predictive ability to be considered a gold standard (10) . 44 
45
The purpose of this study was to use machine learning to identify novel molecular 46 features associated with NAFLD and combine these with conventional clinical 47 variables to predict NAFLD. These models include those variables that are likely to be 48 informative of disease etiology, some of which may be of use in clinical practice. 49
METHODS AND MATERALS 50 51
Participants (IMI DIRECT) 52
The primary data utilized in this study were generated within the IMI DIRECT 53 consortium, which includes a multicenter prospective cohort study of 3029 adults 54 recently diagnosed with T2D (n=795) or at high risk of developing the disease 55 (n=2234). All participants provided informed consent and the study protocol was 56 approved by the regional research ethics committees for each clinical study center. 57
Details of the study design and the core characteristics are explained elsewhere (13, 58 14) . 59 60
Measures (IMI DIRECT) 61
A T2*-based multiecho technique was used to derive liver fat content from MRI (15, 62 16 ) and the percentage values were categorized into fatty (³5%) or non-fatty 63 concentrations (<5%) to define the outcome variable. We elected not to attempt 64 quantitative prediction of liver fat content, as this would require a much larger dataset 65 to be adequately powered. A frequently-sampled 75g oral glucose tolerance test 66 (OGTT) or a frequently sampled mixed-meal tolerance test (MMTT) was performed, 67 from which measures of glucose and insulin dynamics were calculated, as previously 68 described (13, 14, 17) . Liver fat data were available for 1514 IMI DIRECT participants 69 (503 diabetic and 1011 non-diabetic). The distribution of the liver fat data among 70 different centers and cohorts is shown in S1 lifestyle factors, are shown in S1 Table. These clinical variables were controlled for 73 center effect by deriving residuals from a linear model including each clinical variable 74 per model; these residuals were then inverse normalized and used in subsequent 75 analyses. A detailed overview of participant characteristics for the key variables is 76 shown in Table 1 for all IMI DIRECT participants with MRI data. There were no 77 substantial differences in characteristics between these participants and those from IMI 78 DIRECT who did not have MRI data (see S2 Table) . Genetic, transcriptomic, proteomic, and metabolomic datasets were used as input omic 86 variables in the analyses. Buffy coat was separated from whole blood, and DNA was 87 then extracted and genotyped using the Illumina HumanCore array (HCE24 v1.0); 88 genotype imputation was performed using the Haplotype Reference Consortium (HRC) 89 and 1000 Genome (1KG) reference panels. Details of the quality control (QC) steps for 90 the genetic data are described elsewhere (14) . Transcriptomic data were generated using 91 RNA-sequencing from fasting whole blood. Only protein-coding genes were included 92 in the analyses, as reads per kilobase of transcript per million mapped reads (RPKM). 93
The targeted metabolomic data of fasting plasma samples were generated using the 94 Biocrates AbsoluteIDQ p150 kit. Additionally, untargeted LC/MS-based metabolomics 95 was used to cover a broader spectrum of metabolites. A combination of technologies 96 and quantitative panels of protein assays were used to generate 'targeted' proteomic 97 data. This included Olink's proximity extension assays (18), sandwich immunoassay 98 kits using Luminex technology (MerckMillipore and R&D Systems, Sweden), 99 microfluidic ELISA assays (ProteinSimple, USA (19) ), as well as protein analysis 100 services from Myriad RBM (Myriad GmbH, Germany) and for hsCRP (MLM Medical 101 Labs GmbH, Germany). In addition, protein data were generated by single-binder 102 assays using highly multiplexed suspension bead arrays (20) . This approach (denoted 103 'exploratory' proteomics) included a combination of antibodies targeting proteins 104 selected by the consortium given published and unpublished evidence for association 105 with glycemic-related traits. More information about data generation and QC of the 106 transcriptomic, proteomic, and metabolomic data are described in the Supporting 107
Information. Technical covariates for transcriptomics include guanine-cytosine mean 108 content, insert size, analysis lane and RNA integrity number, cell composition, date and 109 center. Technical covariates for proteomics were center, assay, plate number and plate 110 layout (n=4), and for the targeted metabolites the technical covariates were center and 111 plate. These technical covariates were used to correct the omics data and the residuals 112 were then extracted from these models and inverse normalized prior to further analyses. 113 114
Feature selection (IMI DIRECT) 115
We developed a series of NAFLD prediction models, comprised of variables that are 116 available within clinical settings, as well as those not currently available in most clinics 117 (see S3 Table) . We had two strategies for selecting the clinical variables: i) we selected 118 variables based on the clinical-accessibility and their established association with fatty 119 liver from existing literature without applying statistical procedures for data reduction 120 (models 1-3); ii) a pairwise Pearson correlation matrix was used for feature selection of 121 the clinical variables by placing a pairwise correlation threshold of r>0.8. We then 122 selected the variables we considered most accessible among those that were collinear 123 (model 4). Feature selection was undertaken in the combined cohort (diabetic and non-124 diabetic) in order to maximize sample size and statistical power. Of 1514 participants 125 with liver fat data, 1049 had all necessary clinical and multi-omics data for a complete 126 case analysis. We used k-nearest neighbors (k-NN) (21) imputation method with k 127 equal to 10 as a means to reduce the loss of sample size but found that this did not 128 materially improve predictive power in subsequent analyses and determined not to 129 include these imputed data. An overview of the pairwise correlations among the clinical 130 variables available in 1049 IMI DIRECT Study participants is presented in Fig 1. The 131 abbreviations used for the variables in the figure are defined in S1 Table. 132 respectively. The abbreviations used for the variables in the figure are defined in S1 138 Table.  139   140 The high-dimensionality nature of omics data also necessitated data reduction using the 141 feature selection tool LASSO prior to building the model. LASSO is a regression 142 analysis method that minimizes the sum of least squares in a linear regression model 143 and shrinks selected beta coefficients ( " ) using penalties (formula (1)). Minimizing 144 the following value, LASSO excludes the least informative variables and selects those 145 features of most importance for the outcome of interest ( ) in a sample of n cases, each 146 of which consists of m parameters. The penalty applied by can be any value from zero 147 to positive infinity and is determined through a cross-validation step (22) . 148
149
To minimize bias (for example by overfitting), we randomly divided the dataset and 152 used 70% (n=735) for feature selection and 30% (n=314) for the model generation (see 153 below). We selected these thresholds for partitioning the dataset in order to maximize 154 the power to select the informative features. Stratified random sampling (23) based on 155 the outcome variable was undertaken in order to preserve the distribution of the liver 156 fat categories in the two feature selection and model generation sets. We selected 157 LASSO, as a non-linear data reduction tool might lead to overfitting owing to the high 158 dimensionality of omics data. LASSO was conducted with package glmnet in R (24) 159 with a ten-fold cross-validation step for defining the parameter that results in the 160 minimum value for the mean square error of the regression model. 161
Feature selection using LASSO was undertaken in each omics dataset (genetic, 162 transcriptomic, proteomic and metabolomic) using 70% of the available data (models 163 5-18). For the genetic dataset, we first performed a genome-wide association study 164 (GWAS) prior to LASSO in order to identify single-nucleotide polymorphisms (SNPs) 165 tentatively associated with liver fat accumulation (P<5 × 10 78 ). LASSO was then 166 applied to these index variants for feature selection in 70% of the study sample. The 167 individual SNP association analysis was conducted with rvTests v2.0.2 (25) , which 168 applies a linear mixed-model with an empirical kinship matrix to account for familial 169 relatedness, cryptic relatedness, and population stratification. Only common variants 170 with minor allele frequency (MAF) greater than 5% contributed to the kinship matrix. 171
Liver fat data was log-transformed and then adjusted for age, age , , sex, center, body 172 mass index (BMI) and alcohol consumption. These values were then inverse normal 173 transformed and used in the GWAS analyses. The remaining 30% of the data was used to develop the binary prediction models for 184 fatty liver (yes/no) with selected features used as input variables. We utilized the 185 Random Forest supervised machine learning method, which is an aggregation of 186 decision trees built from bootstrapped datasets (a process called 'bagging'). Typically, 187 two-thirds of the data are retained in these bootstrapped datasets and the remaining third 188 is termed the 'out of bag' dataset (OOB), the latter of which is used to validate the 189 performance of the model. 
204 Balanced Accuracy was also evaluated, which is the proportion of individuals correctly 205 classified (true positives and true negatives) within each class individually. 206
Measurements of sensitivity, specificity, F1 score and balanced accuracy were 207 computed and compared at different cut-offs for diabetic, non-diabetic and the 208 combined cohorts. The variable importance was also determined via a "permutation 209 accuracy importance" measure using Random Forest. In brief, for each tree, the 210 prediction accuracy was calculated in the OOB test data. Each predictor variable was 211 then permuted and the accuracy was recalculated. The difference in the accuracies was 212 averaged over all the trees and then normalized by the standard error. Accordingly, a 213 measure for variable importance is the difference in prediction accuracy before and 214 after the permutation for each variable (27) . Statistical analyses were undertaken using 215 R software version 3.2.5 (28) and the Random Forest models were built using the Caret 216 package (29) . These included the fatty liver index (FLI) (30) , hepatic steatosis index (HSI) (31) and 227 NAFLD liver fat score (NAFLD-LFS) (32) . 228
FLI 230
The FLI is commonly used to estimate the presence or absence of fatty liver 231 (categorized into fatty (>=60) or non-fatty liver (<60) FLI units) (30) . 
External validation (UK Biobank cohort) 251
The UK Biobank cohort (34) was used to validate the clinical prediction models 252 (models 1 and 2) derived using IMI DIRECT data (UK Biobank application ID: 18274). 253
The same protocol and procedure have been used to quantify MRI-derived liver fat in 254 IMI DIRECT and UK Biobank (16) . In addition, we validated the FLI and HSI using 255 UK Biobank data. Field numbers for the UK Biobank variables used in the validation 256 step can be found in the S4 Table. The data analysis procedures used for the UK 257
Biobank validation analyses mirror those used in IMI DIRECT (as described above). 258
259

RESULTS 260
The following section describes fatty liver prediction models that are likely to suit 261 different scenarios. We focus on a basic model (model 1), which includes variables that 262 are widely available in both clinical and research settings. We aimed to find the optimal cut-off for these models based on the cross-310 validated balanced accuracy. The highest balanced accuracy for models 1-3 in the non-311 diabetic, diabetic and combined cohorts were observed at cut-offs of 0.4, 0.6 and 0.4, 312 respectively (see Table 2 ). 313 HbA1c, 3807 participants had data available for a complete case analysis. Given the 334 limited availability of variables in the UK Biobank dataset, only models 1 and 2 of the 335 NAFLD prediction models we developed could be externally validated. To facilitate 336 this validation analysis, the Random Forest models developed in the IMI DIRECT 337 cohorts were used to predict the liver fat category (fatty vs. non-fatty) for the UK 338 Biobank participants. The performance of FLI and HSI was also tested in the UK 339 Biobank cohort. We validated both models 1 and 2 in the UK Biobank cohort with a 340 similar ROCAUC as seen in the IMI DIRECT dataset. The ROCAUCs were 0.71 (95% 341 CI= 0.69, 0.73), 0.79 (95% CI= 0.77, 0.80), and 0.78 (95% CI= 0.76, 0.79), for model 342 1 and model 2 (with fasting glucose or with HbA1c), respectively. The FLI had a 343 ROCAUC of 0.78 (95% CI= 0.76, 0.80), which is similar to model 2. The HSI yielded 344 a ROCAUC of 0.76 (95% CI= 0.75, 0.78). 345
Measurements of sensitivity, specificity, F1 score and balanced accuracy were also 346 computed at the optimal cut-off values for these models: 0.4 for clinical models 1and 347 2; 60 for FLI; 36 for HSI, respectively (see Table 2 ). 348 349 350
Omics models separately or in combination with clinical variables (models 5-14) 351
More advanced models using omics data were also developed. These models were 352 generated using the omics features selected by LASSO in the combined cohorts. The A web interface for the diagnosis of NAFLD was developed using the findings 412 described above (www.predictliverfat.org), which we anticipate will render the models 413
(1-3) developed here accessible for the wider community of clinicians and researchers. 414
DISCUSSION 415
Using data from the IMI DIRECT consortium, we developed 18 diagnostic models for 416 early-stage NAFLD. These models were developed to reflect different scenarios within 417 which they might be used: these included both clinical and research settings, with the 418 more complex (and less accessible) models having the greatest predictive ability. The 419 models were successfully validated in the UK Biobank, where data permitted. Overall, 420 the basic clinical variables proved to be stronger predictors of the fatty liver than more 421 complex omics data, although adding omics data yielded the most powerful model, with 422 very good cross-validated predictive ability (ROCAUC=0.84). 423 NAFLD is etiologically complex, rendering its prevention and treatment difficult, and 424 diagnosis can require invasive and/or relatively expensive procedures. Thus, non-425 invasive and cost-effective prediction models with good sensitivity and specificity are 426 much needed. This is especially important because if NAFLD is detected early, 427 treatment through lifestyle interventions can be highly effective (35). However, simple 428 NAFLD is usually asymptomatic and many patients only come to the attention of 429 hepatologists when serious complications arise (36) . 430
To date, several prediction models have been developed to facilitate the diagnosis of 431 steatosis (thoroughly reviewed elsewhere (11)). FLI is the most well-established and 432 commonly used index, initially developed using ultrasound-derived hepatic steatosis 433 data (30) . The FLI yielded similar predictive performance in the diabetic and non-434 diabetic cohorts of IMI DIRECT (ROCAUC ~ 0.75). 435
Though commonly used for liver fat prediction, the FLI has a similar discriminative 436 ability as waist circumference alone (37) . Better discrimination can be obtained by 437 incorporating additional serological and hemostatic measures, which is the case with 438 the NAFLD-LFS (12), the SteatoTest (38) and the HSI (31), for example. 439
Notwithstanding the added complexity and cost of these scores, the FLI, HSI and the 440 NAFLD-LFS yielded similar predictive ability in a series of liver biopsy-diagnosed 441 NAFLD cases (n=324) (32) . 442
Omics technologies have been used in a small number of studies to identify molecular 443 biomarkers of NAFLD (39) (40) (41) . This includes tests utilizing genetic data such as 444 FibroGENE for staging liver fibrosis (42) , and tests using metabolomic data derived 445 from liver tissue to differentiate simple hepatitis from NASH (43) , as well as a multi-446 we selected cut-offs that maximize balanced accuracy (considering both sensitivity and 472 specificity); these features are especially important in screening algorithms, where the 473 cost of false negatives can be high. Models 1-3 resulted in higher sensitivity in the 474 diabetic cohort than the non-diabetic cohort, whereas the specificity was higher in the 475 non-diabetic and in both cohorts combined than in the diabetic cohort. 476
It is noteworthy that the analytical methods deployed here required a complete case 477 analysis, which diminishes sample size considerably and is, thus, a limitation of this 478 approach; although imputing missing data here helped preserve sample size, it did not 479 improve the prediction ability of the models, and we hence elected to use the complete 480 case analysis. The linear Lasso method was used to minimize overfitting that can occur 481 with high-dimensionality data, while Random Forests was used to identify non-linear 482 associations where data structure allowed. 483
Heavy alcohol consumption is a key determinant of fatty liver but is unlikely to be a 484 major etiological factor in IMI DIRECT owing to the demographics of this cohort. 485
Nevertheless, a further limitation of this analysis is that alcohol intake was self-reported 486 and may lack validity. To address this limitation, we removed all self-reported heavy 487 alcohol consumers from the UK Biobank cohort and undertook sensitivity analyses, but 488 this did not materially affect the results. A further consideration for future work is the 489 impact lifestyle and medications are likely to have on the prediction of NAFLD. Here 490 we considered lifestyle variables, but not medications. However, the use of medicines 491 affecting liver fat is likely to be less in the non-diabetic than in the diabetic cohorts, yet 492 the models fit better in the latter, suggesting that glucose-lowering medication use in 493 the DIRECT cohorts does not have a major detrimental impact on prediction model 494 performance. 495
In summary, we have developed prediction models for NAFLD that may have utility 496 for clinical diagnoses and research investigations alike. Our finding that a model 497 focused on proteomic data yielded high predictive utility may warrant further 498 investigation. Our analysis also suggests that insulin sensitivity and beta-cell 499 dysfunction may be involved in liver fat accumulation, which are at present not 500 considered as features of conventional NAFLD risk models. 501 502 ACKNOWLEDGMENTS 503
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